KAF 156

Drug Profile

KAF 156

Alternative Names: GNF156; KAF-156

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Antimalarials; Imidazoles; Piperazines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Falciparum malaria; Vivax malaria

Most Recent Events

  • 29 May 2017 Novartis plans a phase II trial for Falciparum malaria (Combination therapy, In children, In adolescents, In adults, In elderly) (NCT03167242)
  • 10 Mar 2017 Phase-II development for Falciparum malaria and Vivax malaria is ongoing in Thailand and Vietnam (PO)
  • 15 Jun 2016 Novartis and Medicines for Malaria Venture expand collaboration to co-develop KAF 156
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top